Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 12037390
Leptin antibodies and method of reducing leptin
granted -
US 12037374
Peptides, hydrogel compositions and methods of use thereof
granted -
US 12036405
System and method of electric-induced acoustic tomography for electrotherapy monitoring
granted -
US 12036269
Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria
granted -
US 12036319
Polyvalent sting activating compositions and uses thereof
granted -
US 12029732
Treatment of vascular and lymphatic disease
granted -
US 12031008
Dendritic macroporous hydrogels prepared by crystal templating
granted -
US 12029777
Serine proteinase inhibitors: Serp-1 and Serp-1 RCL-derived peptides effect on microbiome composition and uses thereof
granted -
US 12030953
Chimeric antigen receptors, compositions, and methods
granted -
US 12031147
Adeno-associated virus virions with variant capsids and methods of use thereof
granted -
US 12030958
Compositions and methods of use of alpha-1 antitrypsin fusion polypeptides
granted -
US 12029745
Effects of LGM2605 on a primate model of asthma
granted -
US 12029759
Compositions and methods for treating neurological disorders
granted -
US 12031136
Treatment for skeletal diseases caused by intracellular protein trafficking defects
granted -
US 12029816
Compositions and methods of making brittle-matrix particles through blister pack freezing
granted -
US 12030911
Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA
granted -
US 12029755
Carbon monoxide-based therapies and implantable devices for the treatment of vascular disease
granted -
US 12023343
Thermo-kinetic mixing for pharmaceutical applications
granted -
US 12025615
Methods of classifying response to immunotherapy for cancer
granted -
US 12024486
Lipocationic dendrimers and uses thereof
granted -
US 12023391
Alpha(v)beta(6) integrin-binding peptides and methods of use thereof
granted -
US 12023388
Detection and treatment of caries and microcavities with nanoparticles
granted -
US 12023394
Vesicle-coated fibers made from crosslinked lipids
granted -
US 12023410
Micro/nanobubble solutions for tissue preservation and generation thereof
granted -
US 12016877
Anticancer compositions and methods for making and using them
granted -
US 12018252
Methods and compositions for identifying neoantigens for use in treating cancer
granted -
US 12018081
Photoconjugation reactions for modification of specific proteins on live cells
granted -
US 12018327
Methods and compositions relating to epoxide hydrolase genes
granted -
US 12018082
Methods and agents for treating infections
granted -
US 12016973
Methods and systems for augmenting immune system responses
granted -
US 12018135
Encapsulation by cross-linking of anionic polymers by pH induced dissociation of cation-chelate complexes
granted -
US 12016948
Micromotors and nanomotors for gastrointestinal diagnosis and treatment applications
granted -
US 12017066
Modulation of extracellular vesicles with electrical stimulation
granted -
US 12013406
Methods of detecting anti-folic acid antibodies and uses thereof
granted -
US 12011390
Lacrimal drug delivery device
granted -
US 12011450
Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof
granted -
US 12012467
Small molecule DCN1 inhibitors and therapeutic methods using the same
granted -
US 12012436
Methods of treating mitochondrial disorders
granted -
US 12011488
Methods of treating mitochondrial disorders
granted -
US 12012437
Methods of treating mitochondrial disorders
granted -
US 12005123
Conjugate of isotretinoin and peptide
granted -
US 12006294
Therapeutic compounds
granted -
US 12006355
Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif)
granted -
US 12005066
Cobinamide compounds as a cyanide, sulfide, or methane-thiol antidote
granted -
US 11999731
EGFR dimer disruptors and use of the same
granted -
US 11998565
Trace element compositions, methods of making and use
granted -
US 11999778
VH4 antibodies and compositions comprising the same
granted -
US 11998521
Use of an RXR agonist in treating drug resistant HER2+ cancers
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory